Two separate preclinical studies reported engineered cellular strategies to improve target engagement. A Nature Chemical Biology paper showed intracellular delivery of multivalent Intrinsically Disordered Regions (IDRs) can induce condensates that boost CAR‑T cytotoxicity against low‑antigen tumors, addressing a major limitation in solid‑tumor CAR‑T activity. Independently, a team led by Heiss, Riise and Hanse engineered chimeric antigen receptors on microglia to enhance selective phagocytosis of Aβ1‑42, demonstrating a cell‑therapy approach to clear pathogenic amyloid in Alzheimer’s models. Both reports advance engineering of noncanonical cell types and intracellular programs to widen adoptive‑cell therapy targets.